Financial Performance - Neurogene reported a net loss of 14.6 million in Q3 2023, reflecting an increase in operating expenses[10]. - General and Administrative (G&A) expenses increased to 3.6 million in Q3 2023, driven by higher employee-related expenses[10]. - Neurogene's total assets decreased to 222.6 million as of December 31, 2023[16]. Research and Development - Research and Development (R&D) expenses rose to 11.6 million in Q3 2023, primarily due to increased clinical trial costs for NGN-401[10]. - Interim clinical data from the NGN-401 trial showed improvements of 28% to 52% on the Rett Syndrome Behavioral Questionnaire (RSBQ) among participants[5]. - Neurogene plans to provide an update on the registrational trial design for NGN-401 in the first half of 2025[3]. - The FDA has allowed Neurogene to proceed with the Phase 1/2 trial using the 1E15 vg dose of NGN-401 after reviewing safety data[3]. - Neurogene completed enrollment of 6 participants in the NGN-101 gene therapy trial for CLN5 Batten disease but does not plan to move forward with the program due to a denied RMAT application[6]. - The company expects to announce additional interim Phase 1/2 clinical data for NGN-401 in the second half of 2025[5]. Cash Position - Cash, cash equivalents, and investments as of September 30, 2024, were 200 million, extending the cash runway into the second half of 2027[9].
Neurogene(NGNE) - 2024 Q3 - Quarterly Results